Alnustone promotes hepatic stellate cell ferroptosis via the DNMT3A/GLS2/SLC7A11 axis

Liver fibrosis is a progressive pathological process driven by chronic liver injury, with hepatic stellate cell (HSC) activation as its core driver. Ferroptosis has been demonstrated to mediate HSC activation, and accumulating evidence indicates that GLS2 and DNMT3A play key regulatory roles in ferroptosis. Consequently, targeting ferroptosis has emerged as a promising therapeutic strategy. Alnustone, a natural diarylheptanoid, exhibits anti-fibrotic potential and hepatoprotective properties. Therefore, this study aimed to investigate the anti-fibrotic effects of alnustone and elucidate its underlying molecular mechanisms. The results revealed that alnustone significantly attenuated CCl 4 -induced liver fibrosis in mice, as evidenced by reduced serum liver injury markers, collagen deposition, and downregulated HSC activation markers (α-SMA, Col1A1). RNA-sequencing and functional experiments confirmed that alnustone induced HSC ferroptosis in vivo and in vitro, characterized by mitochondrial cristae loss and elevated ferroptosis hallmarks. The ferroptosis inhibitor ferrostatin-1 abrogated alnustone’s HSC-inactivating effects in vitro. Mechanistically, alnustone targeted and suppressed DNMT3A expression, promoting GLS2 demethylation and upregulation. Co-IP and molecular docking confirmed that GLS2 interacted with SLC7A11 to negatively regulate its expression, thereby facilitating HSC ferroptosis. In addition, DNMT3A overexpression reversed alnustone-induced GLS2 upregulation and ferroptosis. Silencing GLS2 suppressed alnustone-induced HSC ferroptosis and inactivation, whereas GLS2 overexpression alleviated liver fibrosis in HSC-specific GLS2-overexpression (GLS2 cKI ) mice after CCl 4 treatment. Collectively, alnustone alleviates liver fibrosis by inducing HSC ferroptosis through the DNMT3A/GLS2/SLC7A11 axis.

Authors

Institutions

Publication Details

Journal
Cell Biology and Toxicology
Published
2026-11-18
DOI
https://doi.org/10.1007/s10565-026-10339-0
Primary Topic
Liver physiology and pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Alnustone promotes hepatic stellate cell ferroptosis via the DNMT3A/GLS2/SLC7A11 axis

Jianjian Zheng, Boyu Lv, Menglu Shu, Mengting Shen et al.
2 links
Cell Biology and Toxicology
Liver physiology and pathology
article

Alnustone promotes hepatic stellate cell ferroptosis via the DNMT3A/GLS2/SLC7A11 axis

Jianjian Zheng, Boyu Lv, Menglu Shu, Mengting Shen, Mengyuan Li, Xiang Su, Weizhi Zhang
article en

Abstract

Liver fibrosis is a progressive pathological process driven by chronic liver injury, with hepatic stellate cell (HSC) activation as its core driver. Ferroptosis has been demonstrated to mediate HSC activation, and accumulating evidence indicates that GLS2 and DNMT3A play key regulatory roles in ferroptosis. Consequently, targeting ferroptosis has emerged as a promising therapeutic strategy. Alnustone, a natural diarylheptanoid, exhibits anti-fibrotic potential and hepatoprotective properties. Therefore, this study aimed to investigate the anti-fibrotic effects of alnustone and elucidate its underlying molecular mechanisms. The results revealed that alnustone significantly attenuated CCl 4 -induced liver fibrosis in mice, as evidenced by reduced serum liver injury markers, collagen deposition, and downregulated HSC activation markers (α-SMA, Col1A1). RNA-sequencing and functional experiments confirmed that alnustone induced HSC ferroptosis in vivo and in vitro, characterized by mitochondrial cristae loss and elevated ferroptosis hallmarks. The ferroptosis inhibitor ferrostatin-1 abrogated alnustone’s HSC-inactivating effects in vitro. Mechanistically, alnustone targeted and suppressed DNMT3A expression, promoting GLS2 demethylation and upregulation. Co-IP and molecular docking confirmed that GLS2 interacted with SLC7A11 to negatively regulate its expression, thereby facilitating HSC ferroptosis. In addition, DNMT3A overexpression reversed alnustone-induced GLS2 upregulation and ferroptosis. Silencing GLS2 suppressed alnustone-induced HSC ferroptosis and inactivation, whereas GLS2 overexpression alleviated liver fibrosis in HSC-specific GLS2-overexpression (GLS2 cKI ) mice after CCl 4 treatment. Collectively, alnustone alleviates liver fibrosis by inducing HSC ferroptosis through the DNMT3A/GLS2/SLC7A11 axis.

Cell Biology and Toxicology
First Affiliated Hospital of Wenzhou Medical University (CN), People's Hospital of Cangzhou (CN)
Good health and well-being
Liver physiology and pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon